Data from a long-term study suggest that testosterone replacement therapy (TRT) for men with hypogonadism may reduce the risk for major adverse cardiovascular events (MACE). Previous studies have yielded conflicting results on whether there is a benefit. The latest results come from a study of 805 men with hypogonadism from Germany and Qatar who were